Devil facial tumor disease (DFTD) is a cancer that can be spread via open wound from Tasmanian devil to Tasmanian devil. William Brown, Project Officer at Department of…
Despite an abundance of preclinical evidence supporting the treatment strategy of combining an IDO1 inhibitor with anti-PD-1/PD-L1 immunotherapy, the results of a recent clinical trial were unable to confirm…
In an observational comparative effectiveness study of targeted vs non-targeted therapy for metastatic renal cell carcinoma (mRCC), older patients saw modest survival advantages when treated with targeted therapies.…
Antoine Azar, MD, clinical director of the Division of Allergy and Immunology at Johns Hopkins Bayview Medical Center, discusses a patient’s journey to diagnosis and treatment of adult…
In this video, Dr. Daniel George, MD, discusses the results of a sunitinib study that helped change the treatment landscape for renal cell carcinoma (RCC). Compared to placebo,…
An interim analysis of the CHECKMATE920 phase IIIb/IV clinical trial found that renal cell carcinoma (RCC) patients with brain metastasis show encouraging anti-tumor activity in response to nivolumab…
